Alligator Bioscience Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
ATORX
- Investments
-
2
Alligator Bioscience General Information
Description
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Contact Information
Website
www.alligatorbioscience.seCorporate Office
- Medicon Village
- Scheeletorget 1
- 223 81 Lund
- Sweden
Corporate Office
- Medicon Village
- Scheeletorget 1
- 223 81 Lund
- Sweden
Alligator Bioscience Stock Performance
As of 20-Nov-2026, Alligator Bioscience’s current market cap is $2.8M with 3.57B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.8M | 3.57B | 35.3M | -$0.06 |
Alligator Bioscience Financials Summary
As of 30-Sep-2026, Alligator Bioscience has a trailing 12-month revenue of $30.1K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,182 | 19,561 | 13,750 | 34,807 |
| Revenue | 30 | 52 | 5,462 | 5,467 |
| EBITDA | (6,661) | (549) | (19,854) | (22,532) |
| Net Income | (8,738) | (5,227) | (22,115) | (23,387) |
| Total Assets | 8,944 | 12,020 | 9,456 | 11,852 |
| Total Debt | 2,779 | 4,689 | 16,387 | 1,655 |
Alligator Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alligator Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Alligator Bioscience Comparisons
Industry
Financing
Details
Alligator Bioscience Competitors (79)
One of Alligator Bioscience’s 79 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| GT Biopharma | Corporation | San Francisco, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA |
Alligator Bioscience Patents
Alligator Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202507480-D0 | Method of predicting responsiveness to therapy | Pending | 15-May-2025 | ||
| GB-202410994-D0 | Novel polypeptides | Inactive | 26-Jul-2024 | ||
| GB-202401084-D0 | Methods | Inactive | 26-Jan-2024 | ||
| GB-202316390-D0 | Combination therapies | Inactive | 26-Oct-2023 | ||
| EP-4695291-A1 | Combination therapies | Pending | 13-Apr-2023 | C07K16/3007 |
Alligator Bioscience Signals
Alligator Bioscience Investments & Acquisitions (2)
Alligator Bioscience’s most recent deal was a Later Stage VC with Peptinovo Biopharma for . The deal was made on 16-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Peptinovo Biopharma | 16-Dec-2024 | Later Stage VC | Drug Delivery | ||
| Atlas Therapeutics | 23-Oct-2013 | Merger/Acquisition | Drug Discovery |
Alligator Bioscience ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
41.58 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Alligator Bioscience Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Atlas Therapeutics | Stockholm, Sweden | 2010 | |
| Alligator Bioscience (CD40 Agonist Antibody Mitazalimab) | Lund, Sweden |
Alligator Bioscience FAQs
-
When was Alligator Bioscience founded?
Alligator Bioscience was founded in 2001.
-
Where is Alligator Bioscience headquartered?
Alligator Bioscience is headquartered in Lund, Sweden.
-
What is the size of Alligator Bioscience?
Alligator Bioscience has 11 total employees.
-
What industry is Alligator Bioscience in?
Alligator Bioscience’s primary industry is Drug Discovery.
-
Is Alligator Bioscience a private or public company?
Alligator Bioscience is a Public company.
-
What is Alligator Bioscience’s stock symbol?
The ticker symbol for Alligator Bioscience is ATORX.
-
What is the current market cap of Alligator Bioscience?
The current market capitalization of Alligator Bioscience is $2.8M.
-
What is Alligator Bioscience’s current revenue?
The trailing twelve month revenue for Alligator Bioscience is $30.1K.
-
Who are Alligator Bioscience’s competitors?
Blueprint Medicines, GT Biopharma, Alnylam Pharmaceuticals, Damora Therapeutics ( Drug Discovery), and AVEO Oncology are some of the 79 competitors of Alligator Bioscience.
-
What is Alligator Bioscience’s annual earnings per share (EPS)?
Alligator Bioscience’s EPS for 12 months was -$0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process